In a new paper published in Movement Disorders, researchers for the first time established a link between the presence of misfolded alpha-synuclein and X-linked dystonia-Parkinsonism, also known as “Lubag.”
Biotech company Gain Therapeutics, Inc. announced positive results from an initial study of two Structurally Targeted Allosteric Regulators (STARs), GT-02287 and GT-02329, for the potential treatment of Parkinson’s and Gaucher disease. Using their Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) platform, Gain analyzes the 3D structure of proteins to identify new treatment targets in neurodegenerative disorders.
Previous research has demonstrated that alpha-synuclein can damage mitochondria, the organelle responsible for cellular energy production, contributing to the progression of Parkinson’s disease. New research from the State University of New York at Buffalo sheds light on the previously undiscovered ways that alpha-synuclein affects mitochondria.
Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as Posiphen), its investigational treatment for Alzheimer’s and Parkinson’s disease. ANVS401 works by inhibiting the formation of beta-amyloid and tau in Alzheimer’s and alpha-synuclein in Parkinson’s, which differs from other drugs that aim to clear these compounds after they’ve formed.
There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder caused by the accumulation of alpha-synuclein in the brain. MSA causes problems with movement, balance, and the control of some involuntary bodily functions such as blood pressure and bowel and bladder function. Last month, Alterity Therapeutics published promising results in Movement Disorders of ATH434 in a mouse model of the disease.
Biopharmaceutical company Seelos Therapeutics in conjunction with researchers at Duke University School of Medicine announced promising results for an epigenome-editing therapy designed to reduce alpha-synuclein levels.
News came last week that after the controversial early-June approval of Aduhelm, the first new treatment for Alzheimer’s disease in almost 20 years, the FDA (at manufacturer Biogen’s request) had narrowed its recommendation of who should receive it.
Parkinson’s disease is caused by the accumulation of alpha-synuclein, a misfolded protein that interferes with the brain’s ability to produce dopamine.
UCB presented data from a Phase 1b study of UCB0599, an oral compound that suppresses alpha-synuclein misfolding, at the American Association of Neurology meeting in April.
Aptinyx, Inc. was forced to suspend its study of NYX-458—a treatment for cognitive impairment in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)—due to the COVID-19 pandemic. Last week the biopharmaceutical company announced that they’ll again start screening patients for their Phase 2 study.